5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

In this article, we discuss the 5 best biotech stocks to buy according to Mark Lampert. If you want to read our detailed analysis of Lampert’s Biotechnology Value Fund, go directly to the 10 Best Biotech Stocks to Buy According to Mark Lampert. 

5. Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Biotechnology Value Fund’s Stake Value: $127,587,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 4.78%
Number of Hedge Fund Holders: 21

Leah Rush Cann of Brookline sees potential in drug development at Kymera Therapeutics, Inc. (NASDAQ:KYMR) and expects the company to launch its first drugs by 2028. Recently, the firm initiated its coverage of the company with a Buy rating and an $88 price target.

Jeremy Green’s Redmile Group is the second-largest shareholder of Kymera Therapeutics, Inc. (NASDAQ:KYMR), owning over 2.5 million shares in the company. In Q2, 21 hedge funds tracked by Insider Monkey reported having stakes in the company, valued at $448.8 million. In the previous quarter, 16 hedge funds owned stakes in the company, highlighting a positive hedge fund sentiment.

BVF owns over 2.6 million shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in Q2, valued at $127.5 million. The company represents 4.78% of the hedge fund’s 13F portfolio.